Why the study?
To compare clinical characteristics, treatment patterns, and 30-day all-cause readmission and mortality in patients hospitalized for heart failure before versus during the COVID-19 pandemic.
Does hospitalization during the COVID-19 pandemic alter 30-day all-cause readmission and mortality in patients with heart failure?
Does hospitalization during the COVID-19 pandemic alter 30-day all-cause readmission and mortality in patients with heart failure?
During the COVID-19 pandemic, patients hospitalized for heart failure experienced lower 30-day readmission rates but higher 30-day all-cause mortality compared to the pre-pandemic period.
Answers are grounded in this paper and cite their sources.
Elevated post-HF hospitalization mortality during COVID-19 signals need for heightened monitoring; leaves open mechanisms and generalizability beyond this cohort.
OBJECTIVE: To compare clinical characteristics, treatment patterns, and 30-day all-cause readmission and mortality between patients hospitalized for heart failure (HF) before and during the coronavirus disease 2019 (COVID-19) pandemic. PATIENTS AND METHODS: The study was conducted at 16 hospitals across 3 geographically dispersed US states. The study included 6769 adults (mean age, 74 years; 56% [5033 of 8989] men) with cumulative 8989 HF hospitalizations: 2341 hospitalizations during the COVID-19 pandemic (March 1 through October 30, 2020) and 6648 in the pre-COVID-19 (October 1, 2018, through February 28, 2020) comparator group. We used Poisson regression, Kaplan-Meier estimates, multivariable logistic, and Cox regression analysis to determine whether prespecified study outcomes varied by time frames. RESULTS: The adjusted 30-day readmission rate decreased from 13.1% (872 of 6648) in the pre-COVID-19 period to 10.0% (234 of 2341) in the COVID-19 pandemic period (relative risk reduction, 23%; hazard ratio, 0.77; 95% CI, 0.66 to 0.89). Conversely, all-cause mortality increased from 9.7% (645 of 6648) in the pre-COVID-19 period to 11.3% (264 of 2341) in the COVID-19 pandemic period (relative risk increase, 16%; number of admissions needed for one additional death, 62.5; hazard ratio, 1.19; 95% CI, 1.02 to 1.39). Despite significant differences in rates of index hospitalization, readmission, and mortality across the study time frames, the disease severity, HF subtypes, and treatment patterns remained unchanged (P>0.05). CONCLUSION: The findings of this large tristate multicenter cohort study of HF hospitalizations suggest lower rates of index hospitalizations and 30-day readmissions but higher incidence of 30-day mortality with broadly similar use of HF medication, surgical interventions, and devices during the COVID-19 pandemic compared with the pre-COVID-19 time frame.
No takes yet. Share an insight, caveat, or question.
Yousufuddin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: